Qualigen Therapeutics Inc
NASDAQ:QLGN
EV/EBIT
Enterprise Value to EBIT
Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.
Market Cap | EV/EBIT | ||||
---|---|---|---|---|---|
US |
Qualigen Therapeutics Inc
NASDAQ:QLGN
|
1.5m USD | -0.2 | ||
US |
Abbvie Inc
NYSE:ABBV
|
288.5B USD | 19.8 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
171.3B USD | 31.4 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.8B USD | 26.4 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.5B USD | 25 | ||
AU |
CSL Ltd
ASX:CSL
|
136.7B AUD | 27.4 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
84.4B USD | 9.2 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
49B USD | -8 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -55.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
34.3B USD | 18.6 | ||
KR |
Celltrion Inc
KRX:068270
|
39.6T KRW | 62.2 |
EV/EBIT Forward Multiples
Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.